Skip to main content
Figure 2 | Journal for ImmunoTherapy of Cancer

Figure 2

From: iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine

Figure 2

Expansion of OVA-specific CTLs and NK cells upon combined CD1d treatment and OVA/CpG immunization. Blood and spleen lymphocytes from CD45.1 mice that received Vα14-Jα18 and OT-I cells and were immunized and treated as in Fig. 1, were monitored at different time points after immunization. A. Left; frequency of H-2Kb/OVA-specific CD8 T cells among total CD8 lymphocytes in the blood at day 3 after immunization. Right; frequency of NK cells in the blood at the same time point. B. Left; frequency of H-2Kb/OVA-specific CD8 T cells among total CD8 lymphocytes in the spleen at day 7 after the immunization. Right; frequency of NK cells among total lymphocytes at the same time point. C. Left; total numbers of H-2Kb/OVA-specific CD8 T cells in the spleen at day 7. Right; total numbers of NK cells in the spleen at the same time point. Bar graphs show frequencies as mean +/α SEM of groups of 5 or 3 mice. Data are representative of 3 independent experiments. *, p <0.05; **, p <0.01; ***, p <0.001; ****, p <0.0001.

Back to article page